Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G, Sances G, Tassorelli C, Baraldi C, Castro FL, Guerzoni S, Prudenzano MP, Fallacara A, Gentile M, Ornello R, Onofri A, Burgalassi A, Chiarugi A, De Cesaris F, Granato A, Casalena A, De Tommaso M, Mampreso E, Merlo P, Coppola G, Battistini S, Rebecchi V, Rainero I, Sepe FN, Dalla Volta G, Sacco S, Geppetti P, Iannone LF; Italian Headache Registry (RICe) Study Group. Caponnetto V, et al. Among authors: casalena a. CNS Drugs. 2023 Dec;37(12):1069-1080. doi: 10.1007/s40263-023-01050-3. Epub 2023 Nov 24. CNS Drugs. 2023. PMID: 37999868 Free PMC article.
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).
Onofri A, Iannone LF, Granato A, Garascia G, Bartole L, Manganotti P, Vollono C, Romozzi M, Sottani C, Calabresi P, Tassorelli C, Sances G, Allena M, De Icco R, De Cesaris F, Burgalassi A, Chiarugi A, Baraldi C, Guerzoni S, Prudenzano MP, Fallacara A, Albanese M, Rainero I, Coppola G, Casalena A, Mampreso E, Pistoia F, Sarchielli P, Morson M, Sacco S, Geppetti P, Ornello R; Italian Headache Registry (RICe) Study Group. Onofri A, et al. Among authors: casalena a. Neurol Sci. 2023 Aug;44(8):2845-2851. doi: 10.1007/s10072-023-06758-0. Epub 2023 Mar 20. Neurol Sci. 2023. PMID: 36939946 Free PMC article.
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.
Ornello R, Baraldi C, Guerzoni S, Lambru G, Fuccaro M, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Dalla Valle E, Mancioli A, Ranieri A, Alfieri G, Latysheva N, Filatova E, Talbot J, Cheng S, Holle D, Scheffler A, Nežádal T, Čtrnáctá D, Šípková J, Matoušová Z, Sette L, Casalena A, Maddestra M, Viola S, Affaitati G, Giamberardino MA, Pistoia F, Reuter U, Sacco S. Ornello R, et al. Among authors: casalena a. Front Neurol. 2021 Dec 16;12:774341. doi: 10.3389/fneur.2021.774341. eCollection 2021. Front Neurol. 2021. PMID: 34975732 Free PMC article.
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Egeo G, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Valle ED, Mancioli A, Ranieri A, Alfieri G, Latysheva N, Filatova E, Talbot J, Cheng S, Holle D, Scheffler A, Nežádal T, Čtrnáctá D, Šípková J, Matoušová Z, Casalena A, Maddestra M, Viola S, Affaitati G, Giamberardino MA, Pistoia F, Reuter U, Sacco S. Ornello R, et al. Among authors: casalena a. J Headache Pain. 2022 Mar 19;23(1):38. doi: 10.1186/s10194-022-01408-w. J Headache Pain. 2022. PMID: 35305579 Free PMC article.
Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study.
De Matteis E, Caponnetto V, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Maddestra M, Viola S, Pistoia F, Sacco S, Ornello R. De Matteis E, et al. Among authors: casalena a. Front Neurol. 2022 Sep 23;13:973226. doi: 10.3389/fneur.2022.973226. eCollection 2022. Front Neurol. 2022. PMID: 36212640 Free PMC article.
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.
Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S. Ornello R, et al. Among authors: casalena a. J Headache Pain. 2020 Aug 15;21(1):102. doi: 10.1186/s10194-020-01171-w. J Headache Pain. 2020. PMID: 32799790 Free PMC article.
Association between response to triptans and response to erenumab: real-life data.
Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, Affaitati G, Giamberardino MA, Viola S, Gabriele A, Pistoia F, Cerone D, Marini C, Sacco S, Ornello R. Frattale I, et al. Among authors: casalena a. J Headache Pain. 2021 Jan 6;22(1):1. doi: 10.1186/s10194-020-01213-3. J Headache Pain. 2021. PMID: 33407070 Free PMC article.
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S. Ornello R, et al. Among authors: casalena a. J Headache Pain. 2020 Apr 7;21(1):32. doi: 10.1186/s10194-020-01102-9. J Headache Pain. 2020. PMID: 32264820 Free PMC article.
29 results